THANK YOU FOR SUBSCRIBING
The company is nationally recognized for its innovative approach to treatments leveraging the immune system, especially its development of novel adjuvants, which are compounds added to therapies to improve or direct an immune response
FREMONT, CA: Biotechnology firm developing immune therapies and components for more effective vaccines, Inimmune, raised USD 22 million in a Series A funding round led by Two Bear Capital, a new firm based in Whitefish, Montana. As part of the investment round Two Bear Capital Founder and Managing Partner Michael Goguen will join Inimmune's board of directors. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer.
"We are excited to partner with Two Bear Capital for this Series A investment. We could have looked outside of Montana for investors but were happy to find a local VC firm that connected with our vision to grow a world-class biotech company right here in Montana," said Dr Jay Evans, President and CEO at Inimmune. Proceeds from the Series A investment round will be used to advance at least two late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Inimmune was founded by co-founders Drs. Kendal Ryter, Helene Bazin-Lee, David Burkhart and Jay Evans in 2016, along with a team of 11 experienced scientists from GlaxoSmithKline. The company is nationally recognized for its innovative approach to treatments leveraging the immune system, especially its development of novel adjuvants, which are compounds added to therapies to improve or direct an immune response. Adjuvants are an essential component in safe, effective vaccines. Besides, Inimmune has also partnered with the University of Montana in the urgent race to develop a vaccine against COVID-19. The company is also advancing immune-based therapies for a variety of other dangerous emerging pathogens, such as antibiotic-resistant infections.
"Effectively harnessing the incredible power of the human immune system has the potential to prevent or cure the most devastating diseases faced by humanity - from Covid-19, to cancer, to neurodegenerative diseases and more - and the need for solutions today is more urgent than ever," said Two Bear Capital's Michael Goguen. "The team at Inimmune combines world-class immunology and vaccine expertise, proven track records and a passion for solving some of the most important medical crises of our time. We are honored to be partners with them as they advance their promising therapies to the next level."
More in News